557
Participants
Start Date
December 19, 2016
Primary Completion Date
April 28, 2022
Study Completion Date
April 28, 2022
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
NKTR 214 + nivolumab at 5 dosage levels.
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab
Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
Hospital Quirón Barcelona, Barcelona
Hospital Clínic de Barcelona, Barcelona
New York University Langone Medical Center - NYU Cancer Institute, New York
Institute for Cancer Research and Treatment (IRCC), Turin
Memorial Sloan-Kettering Cancer Center, New York
L'Institut Paoli - Calmettes, Marseille
Assistance Publique Hopitaux de Marseille - Hopital Nord, Marseille
Roswell Park Cancer Institute, Buffalo
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Istituto Europeo di Oncologia, Milan
Inova Fairfax Hospital, Fairfax
Virginia Cancer Specialists, PC, Fairfax
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Centro Integral Oncológico Clara Campal (CIOCC), Madrid
Emory University Hospital, Atlanta
Clínica Universidad de Navarra, Pamplona
University of Florida, Gainesville
Orlando Health Inc., Orlando
Campus Hospital Universitario Virgen del Rocío - Instituto de Biomedicina de Sevilla (IBIS), Seville
Institut de Cancerologie de l'Ouest, Saint-Herblain
Indiana University Health Melvin & Bren Simon Cancer Center, Indianapolis
Henry Ford Hospital, Detroit
Azienda Ospedaliera Universitaria Senese, Siena
Loyola University Medical Center, Chicago, Maywood
Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznan
Med-Polonia Sp. z o.o., Poznan
Washington University School of Medicine in St. Louis, St Louis
University of Kansas Cancer Center, Kansas City
Centre Léon Bérard, Lyon
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado, Denver, Denver
"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale", Napoli
Szpitale Pomorskie Sp. z o.o., Gdynia
UCLA, Los Angeles
UCSD, Moores Cancer Center, La Jolla
Instytut Medyczny Santa Familia Sp. z o. o. w Łodzi, Lodz
Stanford Cancer Institute, Stanford
Gustave Roussy, Villejuif
Providence Portland Medical Center, Portland
Seattle Cancer Care Alliance, Seattle
Yale School of Medicine, New Haven
Dana-Farber Cancer Institute, Boston
Antwerp University Hospital, Edegem
Vzw Az Groeninge, Kortrijk
UZ Leuven, Leuven
CHU de Liège, Liège
GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk
BC Cancer Agency Vancouver Centre, Vancouver
Jewish General Hospital, Montreal
Sunnybrook Health Sciences Centre, Toronto
Princess Margaret Cancer Centre, Toronto
Azienda Ospedaliera San Camillo-Forlanini, Roma
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza, Brzozów
Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock
The Royal Marsden NHS Trust, London
Mount Vernon Cancer Centre, Northwood
The Christie NHS Foundation Trust, Withington
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Nektar Therapeutics
INDUSTRY